Trends in co-prescribing of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in Ireland. - Test2 - elhamkhani - TriplyDB

Trends in co-prescribing of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in Ireland.

Trends in co-prescribing of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in Ireland.

http://www.wikidata.org/entity/Q34609043

about

New prescriptions of spironolactone associated with angiotensin-converting-enzyme inhibitors and/or angiotensin receptor blockers and their laboratory monitoring from 2001 to 2008: a population study on older people living in the community in Italy.The impact of regulatory action on the co-prescribing of renin-angiotensin system blockers in UK primary care.Dual blockade of the renin-angiotensin system with angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs).The effect of free health care on polypharmacy: a comparison of propensity score methods and multivariable regression to account for confounding.Combined use of drugs inhibiting the renin-angiotensin system: prescribing patterns and risk of acute kidney injury in German nursing home residents.

P2860

Q38045164-F0E1C8D6-EB56-4805-A0B8-40F2A3E8FCDB Q38789941-74FA67D5-FF4C-4A3C-B82F-5E1A426EA889 Q42635555-A1C8B0D1-022D-4383-801D-4E172038C56A Q48325085-822563B4-9DAC-4109-A349-548FE42E1D7B Q55325163-65D26C40-BCEC-44EE-9C63-A5A29B7858EF

P2860

Trends in co-prescribing of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in Ireland.

http://www.wikidata.org/entity/Q34609043

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Trends in co-prescribing of an ...... receptor blockers in Ireland.

@ast

Trends in co-prescribing of an ...... receptor blockers in Ireland.

@en

Trends in co-prescribing of an ...... receptor blockers in Ireland.

@nl

type

label

Trends in co-prescribing of an ...... receptor blockers in Ireland.

@ast

Trends in co-prescribing of an ...... receptor blockers in Ireland.

@en

Trends in co-prescribing of an ...... receptor blockers in Ireland.

@nl

prefLabel

Trends in co-prescribing of an ...... receptor blockers in Ireland.

@ast

Trends in co-prescribing of an ...... receptor blockers in Ireland.

@en

Trends in co-prescribing of an ...... receptor blockers in Ireland.

@nl

P1433

Q34609043-8C4A9EFF-1800-422E-AFD8-F9B11335947C

P1476

Q34609043-AA84736C-C3C0-4849-BE8C-E41EFEA3076E

P2093

Q34609043-016541D4-6373-4C49-95ED-1BBA9706AA8E

Q34609043-07F389AE-8E61-4315-B1CB-898ED7C3B41C

Q34609043-4791512A-5560-41E5-8732-EEAF607FCBD0

Q34609043-8CD72677-AE1C-4875-B016-0B6BDA882C1D

P2860

Q34609043-056B58B3-1795-4605-9402-10B3E0E4B714

Q34609043-06043423-652A-4759-AEB8-A51B0923AA1C

Q34609043-0AA72ABD-680F-4365-A4DC-31361E0F8D9E

Q34609043-1733E8DF-C79F-4743-8EDB-5A44DC3AF7A4

Q34609043-234192E2-04BD-45C4-B9CC-866A8E81EC85

Q34609043-25BEE6C6-6560-4B3D-9F9E-7150D9BAE23B

Q34609043-291F82C7-7348-4749-A718-8EFB08E7F297

Q34609043-31A83AE7-82D9-4260-AE37-44E1662EB6A4

Q34609043-34E85319-47E2-435A-B006-20DFD45A6CC6

Q34609043-439CF08C-FDA0-48DD-B1FD-4FA4795377F0

P304

Q34609043-222C2635-1282-4B15-8583-FF3529CB2C7A

P31

Q34609043-D35287D7-F8C9-4FC9-AEC9-0458CF63B942

P356

Q34609043-FC9AF178-EC21-4758-87D6-B926AE230D5B

P407

Q34609043-A5F3C31C-036A-4C3B-AEB9-224920BB810C

P433

Q34609043-F338DF09-C4E1-436D-A119-BF7DF983B216

P478

Q34609043-A2260EF6-7B84-4FB2-A947-7A6F837287DF

P577

Q34609043-321D3AD7-0025-4C7A-AA59-E5CB8C062FF3

P5875

Q34609043-6420657D-9CA9-4620-BC61-F5A88BC2C9F7

P698

Q34609043-E1807B5F-D9EF-4794-89EE-FB763EE0EDDD

P932

Q34609043-FB674788-9697-4409-9F27-A82C783547BB

P356

J.1365-2125.2010.03835.X

P1433

British Journal of Clinical Pharmacology

P1476

Trends in co-prescribing of an ...... receptor blockers in Ireland.

@en

P2093

Catherine A Wall

http://www.w3.org/2001/XMLSchema#string

Kathleen Bennett

http://www.w3.org/2001/XMLSchema#string

Nur L Zaharan

http://www.w3.org/2001/XMLSchema#string

Wan A H Wan Md Adnan

http://www.w3.org/2001/XMLSchema#string

P2860

Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology:

Changes in prevalence of and prescribing for ischaemic heart disease in Ireland 1990-2002

Inequalities in prescribing of secondary preventative therapies for ischaemic heart disease in Ireland

Under-prescribing of cardiovascular therapies for diabetes in primary care

Gap between guidelines and management of patients with acute coronary syndrome without persistent ST elevation. Finnish prospective follow-up survey

Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?

The diagnosis of heart failure in general practice: implications for the UK National Service Framework.

A chronic disease score from automated pharmacy data.

Using pharmacy data to identify those with chronic conditions in Emilia Romagna, Italy.

Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data.

P304

458-466

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2125.2010.03835.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

71

http://www.w3.org/2001/XMLSchema#string

P577

2011-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49801636

http://www.w3.org/2001/XMLSchema#string

P698

21284706

http://www.w3.org/2001/XMLSchema#string

P932

3045556

http://www.w3.org/2001/XMLSchema#string